LQAI1.940%
as of Oct 22
PFE
GrowthPFIZER INC
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.
Close · 3M
+15.50%
Held by 2 AI ETFs
AIVL0.575%
as of Oct 23
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals19
Win rate89% (17/19)
Avg buy return+4.30%
LQAI · Accumulation · 5d
weight 1.750% → 1.940% (+0.190 pp)·stock up 7.9% in the 30 days before
Oct 22·entry $30.42·now $30.03Fresh
-1.28%
since Oct 22
LQAI · Accumulation · 5d
weight 1.740% → 1.900% (+0.160 pp)·stock up 8.5% in the 30 days before
Oct 20·entry $30.11·now $30.03Fresh
-0.27%
since Oct 20
LQAI · Accumulation · 5d
weight 1.720% → 1.870% (+0.150 pp)·stock up 6.4% in the 30 days before
Oct 19·entry $29.44·now $30.03Fresh
+2.00%
since Oct 19
LQAI · Accumulation · 6d
weight 1.710% → 1.890% (+0.180 pp)·stock up 7.0% in the 30 days before
Oct 16·entry $29.58·now $30.03Fresh
+1.52%
since Oct 16
LQAI · Accumulation · 6d
weight 1.680% → 1.850% (+0.170 pp)·stock up 7.2% in the 30 days before
Oct 15·entry $29.44·now $30.03Fresh
+2.00%
since Oct 15
LQAI · Accumulation · 5d
weight 1.700% → 1.840% (+0.140 pp)·stock up 6.0% in the 30 days before
Oct 14·entry $29.21·now $30.03Drifting
+2.81%
since Oct 14
LQAI · Weight increase · 4d
weight 1.680% → 1.760% (+0.080 pp)·stock up 2.5% in the 30 days before
Oct 12·entry $28.40·now $30.03Drifting
+5.74%
since Oct 12
LQAI · Weight increase · 3d
weight 1.680% → 1.740% (+0.060 pp)·stock up 2.3% in the 30 days before
Oct 9·entry $28.28·now $30.03Drifting
+6.19%
since Oct 9
LQAI · Weight increase · 2d
weight 1.680% → 1.720% (+0.040 pp)·stock up 0.1% in the 30 days before
Oct 8·entry $27.82·now $30.03Drifting
+7.94%
since Oct 8
LQAI · Weight decrease · 6d
weight 1.810% → 1.680% (-0.130 pp)·stock down 3.3% in the 30 days before
Oct 6·entry $27.50·now $30.03
+9.20%
since Oct 6
LQAI · Weight decrease · 5d
weight 1.810% → 1.700% (-0.110 pp)·stock down 4.9% in the 30 days before
Oct 5·entry $27.41·now $30.03
+9.56%
since Oct 5
LQAI · Weight decrease · 4d
weight 1.810% → 1.720% (-0.090 pp)·stock down 4.2% in the 30 days before
Oct 2·entry $27.80·now $30.03
+8.02%
since Oct 2
LQAI · Weight decrease · 3d
weight 1.810% → 1.750% (-0.060 pp)·stock down 1.5% in the 30 days before
Oct 1·entry $28.12·now $30.03
+6.79%
since Oct 1
LQAI · Weight decrease · 2d
weight 1.810% → 1.790% (-0.020 pp)·stock up 0.2% in the 30 days before
Sep 30·entry $28.52·now $30.03
+5.29%
since Sep 30
LQAI · Weight increase · 4d
stock up 2.5% in the 30 days before
Sep 28·entry $28.72·now $30.03Drifting
+4.56%
since Sep 28
LQAI · Weight increase · 3d
stock up 1.3% in the 30 days before
Sep 25·entry $28.67·now $30.03Drifting
+4.74%
since Sep 25
LQAI · Weight increase · 2d
stock down 0.6% in the 30 days before
Sep 24·entry $28.41·now $30.03Drifting
+5.70%
since Sep 24
+8.26%
since Sep 21
+8.57%
since Sep 18
AIVL · Weight decrease · 5d
weight 0.575% → 0.541% (-0.034 pp)·stock down 3.3% in the 30 days before
Oct 6·entry $27.50·now $30.03
+9.20%
since Oct 6
AIVL · Weight decrease · 4d
weight 0.575% → 0.543% (-0.032 pp)·stock down 4.9% in the 30 days before
Oct 5·entry $27.41·now $30.03
+9.56%
since Oct 5
AIVL · Weight decrease · 3d
weight 0.575% → 0.555% (-0.020 pp)·stock down 4.2% in the 30 days before
Oct 2·entry $27.80·now $30.03
+8.02%
since Oct 2
AIVL · Weight decrease · 2d
weight 0.575% → 0.564% (-0.011 pp)·stock down 1.5% in the 30 days before
Oct 1·entry $28.12·now $30.03
+6.79%
since Oct 1
AIVL · Accumulation · 5d
weight 0.545% → 0.573% (+0.028 pp)·stock up 0.2% in the 30 days before
Sep 30·entry $28.52·now $30.03Drifting
+5.29%
since Sep 30
AIVL · Accumulation · 5d
weight 0.546% → 0.575% (+0.029 pp)·stock up 2.7% in the 30 days before
Sep 29·entry $28.72·now $30.03Drifting
+4.56%
since Sep 29
+4.56%
since Sep 28
+4.74%
since Sep 25
+5.70%
since Sep 24
+6.56%
since Sep 23
AIVL · Weight increase · 3d
stock down 2.1% in the 30 days before
Sep 18·entry $27.66·now $30.03Drifting
+8.57%
since Sep 18
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Sep 20
The AI ETF activity presents a mixed picture, with AIVL showing an increasing weight trend while BUZZ exited and LQAI decreased its allocation. This contrasts with a Buffett-style "Fail" verdict, as the framework flags Pfizer's poor financial health and lack of margin of safety, suggesting some AI funds might be betting on future improvements or growth catalysts not reflected in current fundamentals.
- Circle of CompetencePfizer operates in the established pharmaceutical industry, whose diversified drug portfolio and recurring sales allow for reasonable projection of ten-year earning power despite R&D and patent challenges.
- Economic MoatPfizer benefits from an enduring economic moat sustained by its vast portfolio of patented drugs, significant R&D scale, and the high regulatory barriers to entry in the pharmaceutical sector.
- ManagementThe provided data does not offer sufficient information to assess management's candor, capital allocation discipline, or skin in the game.
- Financial HealthThe company's reported ROE of 4.89% falls significantly below the required 10-year average of 15% and the minimum 10% in any single year.
- Margin of SafetyCurrent valuation metrics such as a high PER of 36.38 and EV/EBITDA of 20.01, combined with low ROE and negative revenue growth, indicate no discernible margin of safety.
Pfizer passes the initial stages concerning its circle of competence and economic moat, suggesting a fundamentally understandable business with competitive advantages. However, the analysis reveals significant concerns regarding the company's financial health, evidenced by a very low Return on Equity that fails the framework's strict profitability criteria. This poor performance, coupled with elevated valuation multiples, indicates a lack of margin of safety, leading to an overall "Fail" verdict.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.